Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 201-209

  Ali, Kamilah ^a   Lund Katz, Sissel ^a   Lawson, John ^a   Phillips, Michael C ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apolipoprotein E; Cyclooxygenase 2; Heparan sulfate proteoglycan; LDL receptor; Vascular smooth muscle cell

Indexed keywords

APOLIPOPROTEIN E; CYCLOOXYGENASE 2; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOLIPOPROTEIN E3; CYCLOOXYGENASE 2; HEPARAN SULFATE PROTEOGLYCANS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; UP-REGULATION;

EID: 38049075292     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.03.038     Document Type: Article

References (45)

1. Weisgraber K.H. Apolipoprotein E structure-function relationships. Adv Protein Chem 45 (1994) 249-302
2. Wetterau J.R., Aggerbeck L.P., Rall Jr. S.C., and Weisgraber K.H. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 263 (1988) 6240-6248
3. Morrow J.A., Segall M.L., Lund-Katz S., et al. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 39 (2000) 11657-11666
4. Ji Z.S., Sanan D.A., and Mahley R.W. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 36 (1995) 583-592
5. Mahley R.W. Apolipoprotein E cholesterol transport protein with expanding role in cell biology. Science 240 (1988) 622-630
6. Curtiss L.K., and Boisvert W.A. Apolipoprotein E and atherosclerosis. Curr Opin Lipdol 11 (2000) 243-251
7. Trommsdorff M., Gotthardt M., Hiesberger T., et al. Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97 (1999) 689-701
8. Boucher P., Gotthardt M., Li W.-P., Anderson R.G.W., and Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300 (2003) 329-332
9. Ohashi R., Mu H., Yao Q., and Chen C. Cellular and molecular mechanisms of atherosclerosis with mouse models. Trends Cardiovasc Med 14 (2004) 187-190
10. Miyata M., and Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14 (1996) 55-61
11. Kothapalli D., Fuki I., Ali K., et al. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest 113 (2004) 609-618
12. Kothapalli D., Stewart S.A., Smyth E.M., et al. Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin A gene expression. Mol Pharmacol 64 (2003) 249-258
13. Paka L., Goldberg I.J., Obunike J.C., et al. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth?. J Biol Chem 274 (1999) 36403-36408
14. Ishigami M., Swertfeger D.K., Hui M.S., Granholm N.A., and Hui D.Y. Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 20 (2000) 1020-1026
15. Ishigami M., Swertfeger D.K., Granholm N.A., and Hui D.Y. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 273 (1998) 20156-20161
16. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
17. Vane J., and Corin R.E. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg 26 (2003) 571-578
18. Bos C.L., Richel D.J., Ritsema T., Peppelenbosch M.P., and Versteeg H.H. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36 (2004) 1187-1205
19. Pidgeon G.P., Tamosiuniene R., Chen G., et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110 (2004) 2701-2707
20. Buerkle M.A., Lehrer S., Sohn H.-Y., et al. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 110 (2004) 2053-2059
21. Davi G., Gresele P., Violi F., et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Circulation 96 (1997) 69-75
22. Wu M.D.K.K., and Thiagarajan M.D.P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 47 (1996) 315-331
23. Muscara M.N., Vergnolle N., Lovren F., et al. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 129 (2000) 1423-1430
24. Schonbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
25. Belton O., Byrne D., Kearney D., Leahy A., and Fitzgerald D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102 (2000) 840-845
26. Cuff C.A., Kothapalli D., Azonobi I., et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 108 (2001) 1031-1040
27. Lund-Katz S., Zaiou M., Wehrli S., et al. Effects of lipid interaction on the lysine microenvironments in apolipoprotein E. J Biol Chem 275 (2000) 34459-34464
28. Fisher C.A., and Ryan R.O. Lipid binding-induced conformational changes in the N-terminal domain of human apolipoprotein E. J Lipid Res 40 (1999) 93-99
29. Lu B., Morrow J.A., and Weisgraber K.H. Conformational reorganization of the four-helix bundle of human apolipoprotein E in binding to phospholipid. J Biol Chem 275 (2000) 20775-20781
30. Raussens V., Fisher C.A., Goormaghtigh E., Ryan R.O., and Ruysschaert J.-M. The low density lipoprotein receptor active conformation of apolipoprotein E. Helix organization in N-terminal domain-phospholipid disc particles. J Biol Chem 273 (1998) 25825-25830
31. Narayanaswami V., Maiorano J.N., Dhanasekaran P., et al. Helix orientation of the functional domains in apolipoprotein E in discoidal high density lipoprotein particles. J Biol Chem 279 (2004) 14273-14279
32. Acharyaa P., Segall M.L., Zaiou M., et al. Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. Biochim Biophys Acta 1584 (2002) 9-19
33. Davignon J.G.R., and Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8 (1988) 1-21
34. Strittmatter W.J., Saunders A.M., Schmechel D., et al. Apolipoprotein E: high-avidity binding to {beta}-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer Disease. PNAS 90 (1993) 1977-1981
35. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., and Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252 (1991) 1817-1822
36. Zaiou M., Arnold K.S., Newhouse Y.M., et al. Apolipoprotein E-low density lipoprotein receptor interaction: influences of basic residue and amphipathic {alpha}-helix organization in the ligand. J Lipid Res 41 (2000) 1087-1095
37. Futamura M., Dhanasekaran P., Handa T., et al. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoproteins of apolipoprotein E-heparan sulfate proteogylcan complex formation on cell surfaces. J Biol Chem 280 (2005) 5414-5422
38. Saito H., Dhanasekaran P., Nguyen D., et al. Characterization of the heparin binding sites in human apolipoprotein E. J Biol Chem 278 (2003) 14782-14787
39. Nimpf J., and Schneider W.J. From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2. Biochim Biophys Acta 1529 (2000) 287-298
40. Swertfeger D.K., and Hui D.Y. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem 276 (2001) 25043-25048
41. Libeu C.P., Lund-Katz S., Phillips M.C., et al. New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem 276 (2001) 39138-39144
42. Innerarity T.L., Friedlander E.J., Rall Jr. S.C., Weisgraber K.H., and Mahley R.W. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem 258 (1983) 12341-12347
43. Swertfeger D.K., Bu G., and Hui D.Y. Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. J Biol Chem 277 (2002) 4141-4146
44. Ruiz J., Kouiavskaia D., Migliorini M., et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res 46 (2005) 1721-1731
45. Perez-Sala D.L.S. Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid Redox Signal 3 (2001) 231-248